West Chester, PA, United States of America

Kenneth Allen Newlander

USPTO Granted Patents = 54 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 4.2

ph-index = 17

Forward Citations = 533(Granted Patents)

Forward Citations (Not Self Cited) = 404(Oct 12, 2025)

Inventors with similar research interests:

Location History:

King of Prussia, PA (US) (2006 - 2007)
West Chester, PA (US) (1988 - 2014)
Collegeville, PA (US) (2007 - 2017)

Company Filing History:

18 out of 2,198

Smithkline Beecham Corporation

patents

15 out of 33

Affinium Pharmaceuticals, Inc.

Smithkline Beckman Corporation

patents

6. 2 out of 92

Glaxosmithkline Intellectual Property (no.2) Limited

patents

7. 1 out of 7

Smithkline Beechman Corporation

patents

8. 1 out of 230

Glaxosmithkline Intellectual Property Development Limited

patents

where one patent can have more than one assignee

Years Active: 1988-2025

Loading Chart...

54 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12247033 - Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors (2025-03-11),

2. 9790212 - Enhancer of zeste homolog 2 inhibitors (2017-10-17),

3. 9505745 - Enhancer of zeste homolog 2 inhibitors (2016-11-29),

4. 9402836 - Indoles (2016-08-02),

5. 9382234 - Enhancer of Zeste Homolog 2 inhibitors (2016-07-05),

6. 9073924 - Azaindazoles (2015-07-07),

7. 9018382 - Indazoles (2015-04-28),

8. 8975291 - Indoles (2015-03-10),

9. 8846935 - Indazoles (2014-09-30),

10. 8765792 - Indoles (2014-07-01),

11. 8637509 - Azaindazoles (2014-01-28),

12. 8633236 - Compounds, compositions and methods (2014-01-21),

13. 8404837 - Quinoline derivatives as P13 kinase inhibitors (2013-03-26),

14. 8329928 - Compounds, compositions and methods (2012-12-11),

15. 8173646 - FAB I inhibitors (2012-05-08),

Title: Kenneth Allen Newlander: Innovator in Cancer Therapeutics

Introduction

Kenneth Allen Newlander, based in West Chester, PA, is a prolific inventor holding a remarkable 53 patents. His contributions to the field of pharmaceuticals, particularly in cancer treatment, showcase his dedication to advancing medical science through innovative inventions.

Latest Patents

Among his latest patents, Newlander has made significant strides with compounds that inhibit the Enhancer of Zeste Homolog 2 (EZH2). The inventions include novel compounds represented by unique formulas that are designed to target EZH2. These compounds are not only pivotal in the development of pharmaceuticals but are also intended for therapeutic use in treating various types of cancers.

Career Highlights

Throughout his career, Kenneth Newlander has worked for notable companies including SmithKline Beecham Corporation and Affinium Pharmaceuticals, Inc. His roles within these organizations have facilitated his research and application of innovative solutions in the pharmaceutical industry.

Collaborations

Newlander has collaborated with distinguished professionals in his field, including William Henry Miller and Steven David Knight. These partnerships have greatly contributed to his innovative endeavors and the successful development of his patented compounds.

Conclusion

Kenneth Allen Newlander’s contributions to cancer therapeutics through his numerous patents position him as a significant figure in pharmaceutical innovation. His work not only exemplifies the importance of research and development but also highlights the ongoing efforts to improve treatment options for cancer patients.

This text is generated by artificial intelligence and may not be accurate.